Stock RLAY RELAY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Relay Therapeutics, Inc.

Equities

RLAY

US75943R1023

Market Closed - Nasdaq
Other stock markets
 01:30:00 22/06/2024 am IST 		5-day change 1st Jan Change
6.94 USD +1.31% Intraday chart for Relay Therapeutics, Inc. -5.06% -36.97%
12/06 Transcript : Relay Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:40 AM
06/06 Transcript : Relay Therapeutics, Inc. - Special Call

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with Rly-2608
Relay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Relay Therapeutics Q4 Loss Widens, Reports No Revenue
Relay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Relay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Relay Therapeutics to Raise $30 Million From Private Placement
Relay Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Relay Therapeutics' Cancer Medicine Benefits Patients, Initial Data Shows; Shares Jump
Relay Therapeutics, Inc. Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
Relay Therapeutics' Q2 Loss Widens
Relay Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Relay Therapeutics Says Dose Escalation Data of RLY-4008 Shows 'Tumor Reductions' in Phase 1/2 Study
Relay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Top Midday Decliners
Relay Therapeutics Reports "Selective Target Engagement" in Early Cancer Trial Data; Shares Slump
Relay Therapeutics, Inc. Announces Initial Clinical Data Demonstrating That Rly-2608 Selectively Targets Multiple PI3KaMutations
Relay Therapeutics Shares Rise After Raymond James Starts Coverage at Outperform
Relay Therapeutics' Q4 Loss Narrows, Revenue Falls
Relay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RLAY Stock
  4. News Relay Therapeutics, Inc.
  5. Other languages